Weekly Archive

Strategic Signals Weekly: Biotech 8-K Events and BD Activity

Licensing deals, strategic reviews, and financing events from regulatory filings. Part of the RxDataLab platform: clinical trials, SEC filings, and hedge fund positioning, linked by company.

Get access Live dashboard →

Genprex, Inc. strategic review ongoing (Reqorsa® Gene Therapy (quaratusugene ozeplasmid))

20 signals 3 licensing 3 strategic 13 financing

MASIMO CORP strategic alternatives announcement

14 signals 3 licensing 3 strategic 8 financing

MeiraGTx Holdings plc/Janssen Pharmaceuticals license event (botaretigene sparoparvovec)

14 signals 1 licensing 12 financing

C4 Therapeutics, Inc./Roche license event (degrader-antibody conjugates (DACs))

12 signals 5 licensing 7 financing

IO Biotech, Inc. strategic alternatives announcement

18 signals 3 licensing 2 strategic 10 financing

Werewolf Therapeutics, Inc. strategic alternatives announcement

16 signals 1 strategic 15 financing

Genprex, Inc. strategic review ongoing (Reqorsa Gene Therapy (quaratusugene ozeplasmid))

14 signals 1 strategic 11 financing

ATARA BIOTHERAPEUTICS INC strategic review ongoing (EBVALLO™)

18 signals 1 licensing 1 strategic 15 financing

BioAtla, Inc. strategic alternatives announcement

20 signals 4 licensing 1 strategic 14 financing

Werewolf Therapeutics, Inc. strategic alternatives announcement

18 signals 1 licensing 2 strategic 14 financing

Genprex, Inc. strategic alternatives announcement

16 signals 1 licensing 1 strategic 13 financing

Genprex, Inc. strategic alternatives announcement

7 signals 1 strategic 6 financing

Entera Bio Ltd. licensing event

12 signals 1 licensing 11 financing

IO Biotech, Inc. strategic alternatives announcement

20 signals 2 licensing 1 strategic 17 financing